Phase I/ Phase II

89bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

89bio Announces Proposed Public Offering of Common Stock

Lead Product(s): BIO89-100

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BIO89-100

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: BofA Securities

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Public Offering July 06, 2020

Details:

89bio intends to use the net proceeds of the offering to accelerate and support its BIO89-100 programs in nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG), for the manufacture and scale up of BIO89-100, and for other general corporate purposes.

GoLiver Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

GoLiver Therapeutics Receives Scientific Advice from EMA on its Clinical Development and Biomanufacturing Strategy for Acute Liver Failure

Lead Product(s): Cell therapy products

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 29, 2020

Details:

European Medicines Agency (EMA) has given a positive scientific advice on its clinical development, pharmaco-toxicological and production strategy plans. With this positive scientific advice, GoLiver Therapeutics has reached an important milestone in its clinical roadmap.

89bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial

Lead Product(s): BIO89-100

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 13, 2020

Details:

The company closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled and delays initiation of its SHTG trial due to the COVID-19 pandemic.